These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 31809538)

  • 1. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.
    Farrell AT; Panepinto J; Carroll CP; Darbari DS; Desai AA; King AA; Adams RJ; Barber TD; Brandow AM; DeBaun MR; Donahue MJ; Gupta K; Hankins JS; Kameka M; Kirkham FJ; Luksenburg H; Miller S; Oneal PA; Rees DC; Setse R; Sheehan VA; Strouse J; Stucky CL; Werner EM; Wood JC; Zempsky WT
    Blood Adv; 2019 Dec; 3(23):3982-4001. PubMed ID: 31809538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
    Farrell AT; Panepinto J; Desai AA; Kassim AA; Lebensburger J; Walters MC; Bauer DE; Blaylark RM; DiMichele DM; Gladwin MT; Green NS; Hassell K; Kato GJ; Klings ES; Kohn DB; Krishnamurti L; Little J; Makani J; Malik P; McGann PT; Minniti C; Morris CR; Odame I; Oneal PA; Setse R; Sharma P; Shenoy S
    Blood Adv; 2019 Dec; 3(23):4002-4020. PubMed ID: 31809537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework.
    Badawy SM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):196-205. PubMed ID: 34889394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.
    Pittman DD; Hines PC; Beidler D; Rybin D; Frelinger AL; Michelson AD; Liu K; Gao X; White J; Zaidi AU; Charnigo RJ; Callaghan MU
    Blood; 2021 Apr; 137(15):2010-2020. PubMed ID: 33067606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
    DeBaun MR; Jordan LC; King AA; Schatz J; Vichinsky E; Fox CK; McKinstry RC; Telfer P; Kraut MA; Daraz L; Kirkham FJ; Murad MH
    Blood Adv; 2020 Apr; 4(8):1554-1588. PubMed ID: 32298430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.
    Liem RI; Lanzkron S; D Coates T; DeCastro L; Desai AA; Ataga KI; Cohen RT; Haynes J; Osunkwo I; Lebensburger JD; Lash JP; Wun T; Verhovsek M; Ontala E; Blaylark R; Alahdab F; Katabi A; Mustafa RA
    Blood Adv; 2019 Dec; 3(23):3867-3897. PubMed ID: 31794601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the future of patient-reported outcomes in sickle-cell disease?
    Singh SA; Bakshi N; Mahajan P; Morris CR
    Expert Rev Hematol; 2020 Nov; 13(11):1165-1173. PubMed ID: 33034214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.
    Brandow AM; Carroll CP; Creary S; Edwards-Elliott R; Glassberg J; Hurley RW; Kutlar A; Seisa M; Stinson J; Strouse JJ; Yusuf F; Zempsky W; Lang E
    Blood Adv; 2020 Jun; 4(12):2656-2701. PubMed ID: 32559294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for treating neuropathic pain in people with sickle cell disease.
    Asnani MR; Francis DK; Brandow AM; Hammond Gabbadon CE; Ali A
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012943. PubMed ID: 31273755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate supplementation in people with sickle cell disease.
    Dixit R; Nettem S; Madan SS; Soe HHK; Abas AB; Vance LD; Stover PJ
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011130. PubMed ID: 29546732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications.
    Asnani MR; Quimby KR; Bennett NR; Francis DK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011175. PubMed ID: 27711980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.
    Dampier CD; Smith WR; Wager CG; Kim HY; Bell MC; Miller ST; Weiner DL; Minniti CP; Krishnamurti L; Ataga KI; Eckman JR; Hsu LL; McClish D; McKinlay SM; Molokie R; Osunkwo I; Smith-Whitley K; Telen MJ;
    Clin Trials; 2013 Apr; 10(2):319-31. PubMed ID: 23539110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
    Coyne KS; Currie BM; Callaghan M; Wyrwich KW; Pease S; Baker CL; Arkin S; Pittman DD
    Eur J Haematol; 2022 Sep; 109(3):226-237. PubMed ID: 35569114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation.
    Byrnes C; Botello-Harbaum M; Clemons T; Bailey L; Valdes KM; Coleman-Cowger VH
    J Natl Med Assoc; 2022 Apr; 114(2):211-217. PubMed ID: 35093266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.